Perspectives on rapid elimination and ultimate global eradication of paralytic poliomyelitis caused by polioviruses

European Journal of Epidemiology

Volumn 7, Issue 2, 1991, Pages 95-120

  Sabin, A B ^a  

^a NONE   (United States)

Author keywords

Annual national days of vaccination; Developing countries; Eradication strategy; Poliomyelitis (Paralytic)

Indexed keywords

GEOGRAPHIC DISTRIBUTION; HUMAN; INFECTION CONTROL; POLIOMYELITIS; REVIEW; VACCINATION;

COMMUNICABLE DISEASE CONTROL; DELIVERY OF HEALTH CARE; DEVELOPING COUNTRIES; DISEASES; HEALTH; HEALTH SERVICES; IMMUNIZATION; INTERNATIONAL AGENCIES; ORGANIZATIONS; PRIMARY HEALTH CARE; UN; VACCINATION; VACCINES; VIRAL DISEASES--PREVENTION AND CONTROL; WHO;

CLIMATE; DEVELOPING COUNTRIES; HUMAN; NATIONAL HEALTH PROGRAMS; POLIOMYELITIS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUSES; POPULATION SURVEILLANCE; VACCINATION; WORLD HEALTH;

EID: 0025869943     PISSN: 03922990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/BF00237353     Document Type: Article

References (90)

1. The national immunization campaign of Turkey
2. Update: Poliomyelitis outbreak — Finland, 1984–1985
3. Progress toward eradicating poliomyelitis from the Americas
4. International task force for disease eradication
5. On the course of mass immunization of the population in the Soviet Union with the live poliovirus vaccine from Albert B. Sabin's strains
6. Evaluation of Sabin live poliovirus vaccine in Japan. VI. Large scale use of vaccine during type 1 poliomyelitis epidemic, 1961
7. Mass vaccination against poliomyelitis in Mexico
8. Revised preliminary report on the Louisiana observations of the natural spread within families of living vaccine strains of poliovirus
9. The Israeli experience in the control of poliomyelitis during a quarter of a century, 1957–1982
10. Estado actual de la campana de erradicacion de la poliomielitis en Cuba
11. Neurovilence in cynomolgus monkeys of enterovirus 71 isolated from a patient with hand, food and mouth disease
12. Vaccine preventable diseases of children: the problem
13. The case for global eradication of poliomyelitis
14. Attenuated type 1 poliovirus vaccine: Its capacity to infect and spread from “vaccinees” within institutional population
15. Discussion in “Vaccines Against Viral and Rickettsial Diseases of Man”
16. Neurological complications of acute hemorrhagic conjunctivitis (a polio-like syndrome in adults)
17. Two voluntary mass immunization programs using Sabin oral vaccine
18. Poliomyelitis in the USA: Virtual elimination of disease caused by wild virus
19. Outbreak of paralytic poliomyelitis in Taiwan
20. Clinical survey techniques to estimate prevalence and annual incidence of poliomyelitis in developing countries
21. Evolution of the poliomyelitis vaccination program in Costa Rica
22. Aspectos de laboratorio en el control de la poliomyelitis en Cuba
23. Identification of Bulgarian strain 258
24. Comparative biochemical studies of type 3 poliovirus
25. Is poliomyelitis a serious problem in developing countries? — the Danfa experience
26. Is poliomyelitis a serious problem in developing countries? — lameness in Ghanian schools
27. Discussion in “Vaccines Against Viral and Rickettsial Diseases of Man”
28. Viral and serological studies in children immunized with live poliovirus vaccine —preliminary report of a large trial conducted in Mexico
29. Use of Sabin's live poliovirus vaccine in Mexico. Results of a large-scale trial
30. Paralytic syndromes associated with noninflammatory cytoplasmic or nuclear neuronopathy: acute paralytic disease in Mexican children, neuropathologically distinguishable from Landry-Guillain-Barré syndrome
31. The control of poliomyelitis in Brazil
32. Cuba: Mass polio vaccination program, 1962–1982
33. Behavior of chimpanzee-avirulent poliomyelitis viruses in experimentally infected human volunteers
34. Properties and behaviour of orally administered attenuated poliovirus vaccine
35. Present position of immunization against poliomyelitis with live virus vaccines
36. Recent studies and field tests with live attenuated poliovirus vaccine
37. Poliomyelitis incidence in the Soviet Union in 1960
38. Oral poliovirus vaccine — recent results and recommendations for optimum use
39. Eradication of poliomyelitis —present status and future prospects
40. Is there an exceedingly small risk associated with oral poliovirus vaccine?
41. Vaccine-associated poliomyelitis cases
42. Oral poliomyelitis vaccine: achievements and problems in worldwide use
43. Vaccination against poliomyelitis in economically underdeveloped countries
44. Paralytic poliomyelitis: old dogmas and new perspectives
45. Eradication of smallpox and elimination of poliomyelits: contrasts in strategy
46. Poliomyelitis
47. Vaccine control of poliomyelitis in the 1980s
48. Inadequate serological surveys for immunity to poliomyelitis — inadequate indicators of immune status of communities using oral poliovirus vaccine and inadequate guides to vaccination policy
49. Strategies for elimination of poliomyelitis in different parts of the world with use of oral poliovirus vaccine
50. Oral poliovirus vaccine: History of its development and use and current challenge to eliminate poliomyelitis from the world
51. Strategy for rapid elimination and continuing control of poliomyelitis and other vaccine preventable diseases of children in developing countries
52. Commentary: Is there a need for a change in poliomyelitis immunization policy?
53. Role of my cooperation with Soviet scientists in the elimination of polio: Possible lessons for relations between the U.S.A. and the USSR
54. Measles, killer of millions in developing countries: strategy for rapid elimination and continuing control
55. Community-wide use of oral poliovirus vaccine. Effectiveness of the Cincinnati program
56. Live, orally given poliovirus vaccine — effect of rapid mass immunization on population under conditions of massive enteric infections with other viruses
57. Residual paralytic poliomyelitis in a tropical region of Brazil, 1969–1977: prevalence surveys in different age groups as indicators of changing incidence
58. Epidemiological, clinical and pathomorphological characteristics of epidemic poliomyelitis-like disease associated with enterovirus type 71
59. Further observations in conjunction with first field trial with live poliovirus vaccine in Czechoslovakia. Epidemiological study (1960)
60. Field trial with Sabin's live poliovirus vaccine in Czechoslovakia 1958–1959
61. Material on the immunological and epidemiological effectiveness of live poliomyelitis vaccine
62. Poliomyelitis in Japan during the period 1962–68 after the introduction of mass vaccination with Sabin vaccine
63. Impacto de las JPS [Jornadas Populares de Salud] en el perfil epidemiologico de las enfermedades prevenibles por vacunas y Malaria
64. Data on poliomyelitis reported to WHO by countries in the American Region, 1951–1974
65. Virus diseases surveillance (Hungary)
66. Expanded programme on immunization-global advisory group